The evidence examining use of oral mTOR inhibitors for TSC has shown that the drug class has the potential for multisystemic effects in TSC not only in treating SEGAs or renal angiomyolipomas, but also TSC-associated seizures, cardiac rhabdomyoma, lymphangioleiomyomatosis, or some of the TSC-associated neuropsychiatric disorders [18,19]. Here, TSC1 is linked to tuberous sclerosis.